ReviewTrends in molecular medicine2023
Adenoviruses in medicine: innocuous pathogen, predator, or partner.
Review in Trends in molecular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- TRIM23 prevents adenovirus replication by p62-mediated selective autophagic degradation of viral E1A protein.PLoS pathogens · 2026Article
- Article
- Drug combination treatment as a strategy for inhibiting human adenovirus replication.Antiviral research · 2026Article
- Resurgence of Human Adenovirus Infections in the Korean Military Following the COVID-19 Pandemic.Journal of Korean medical science · 2026Article
- Inhibition of RNA splicing is a novel therapeutic strategy for disruption of nuclear replicating viruses.bioRxiv : the preprint server for biology · 2026Article
- Identification of Novel Recombinant Human Adenovirus Genotype B117 from Pediatric Cases, China.Emerging infectious diseases · 2026Article
- Isoxazole derivatives as multi-target agents: virucidal, antibacterial, and antiproliferative effects on skin cancer cells.Pharmacological reports : PR · 2026Article
- Gene therapy for liver diseases: methods, challenges and opportunities.Journal of nanobiotechnology · 2026Review
- Detection of AdenoviralInternational journal of molecular sciences · 2026Article
- Pediatric adenovirus infections: 10-year clinical spectrum and predictors of severe disease with emphasis on comorbidities and coinfections.European journal of pediatrics · 2026Observational
- Review
- Breaking barriers: Respiratory viral strategies targeting the host's nuclear pore complex and nuclear transport pathways.Molecular biology of the cell · 2026Review
- Adenoviral E3/49K: CD45-targeted immune evasion and therapeutic potential.Frontiers in cellular and infection microbiology · 2026Review
- Molecular arms races at the virus-host splicing interface and their pathogenic implications.Frontiers in microbiology · 2026Review
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Viral eye: Emerging insights into corneal and ocular surface viral infections.World journal of virology · 2025Review
- Multicenter clinical performance and comparative evaluation of the LIAISON PLEX RespiratoryJournal of clinical microbiology · 2025Article
- Epidemiology of Respiratory Adenovirus Infections Among Hospitalized Children in Hainan Province, China, 2021-2024.Pathogens (Basel, Switzerland) · 2025Article
- Early-life infection dynamics and genomic diversity of adenoviruses in a wild primate (Microbial genomics · 2025Article
- Oncolytic virus and immunogenic cell death in cancer therapy.Tumour virus research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The consequences of human adenovirus (HAdV) infections are generally mild. However, despite the perception that HAdVs are harmless, infections can cause severe disease in certain individuals, including newborns, the immunocompromised, and those with pre-existing conditions, including respiratory or cardiac disease. In addition, HAdV outbreaks remain relatively common events and the recent emergence of more pathogenic genomic variants of various genotypes has been well documented. Coupled with evidence of zoonotic transmission, interspecies recombination, and the lack of approved AdV antivirals or widely available vaccines, HAdVs remain a threat to public health. At the same time, the detailed understanding of AdV biology garnered over nearly 7 decades of study has made this group of viruses a molecular workhorse for vaccine and gene therapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.